Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644266 | 0.87 | CYP2C9 (0.82) | CYP2C9 | |
| SCHEMBL2905758 | 0.86 | CYP2C9 (0.74) | CYP2C9 | |
| SCHEMBL10165695 | 0.78 | CYP2C9 (0.84) | CYP2C9 | |
| SCHEMBL2905677 | 0.78 | CYP2C9 (0.63) | CYP2C9 | |
| SCHEMBL10165691 | 0.76 | CYP2C9 (0.61) | CYP2C9 | |
| SCHEMBL2916716 | 0.75 | CYP2C9 (0.59) | CYP2C9 | |
| SCHEMBL10149140 | 0.75 | CYP2C9 (0.59) | CYP2C9 | |
| SCHEMBL20644349 | 0.75 | CYP2C9 (0.59) | CYP2C9 | |
| SCHEMBL20644351 | 0.75 | CYP2C9 (0.60) | CYP2C9 | |
| SCHEMBL10149217 | 0.75 | CYP2C9 (0.81) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-10-01 | — | — | US | disclosed |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-08-06 | — | — | US | disclosed |
| WO-2019012149-A1 | THERAPEUTIC MODULATORS OF THE REVERSE MODE OF ATP SYNTHASE | FORREST MICHAEL DAVID (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | ATP5ME, ATP5F1A, ATP5MG | CYP2C9 2626/4885 |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | ATP5ME, ATP5MG, ATP5F1A | CYP2C9 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.